These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20603272)

  • 21. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
    Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
    Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes.
    Delaitre C; Boisbrun M; Lecat S; Dupuis F
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling.
    Du N; Feng J; Hu LJ; Sun X; Sun HB; Zhao Y; Yang YP; Ren H
    Oncol Rep; 2012 Jun; 27(6):1893-903. PubMed ID: 22426690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.
    Uemura H; Nakaigawa N; Ishiguro H; Kubota Y
    Curr Cancer Drug Targets; 2005 Aug; 5(5):307-23. PubMed ID: 16101380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide.
    Miura S; Nakayama A; Tomita S; Matsuo Y; Suematsu Y; Saku K
    Clin Exp Hypertens; 2015; 37(5):353-7. PubMed ID: 25496380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography.
    Zhang H; Unal H; Gati C; Han GW; Liu W; Zatsepin NA; James D; Wang D; Nelson G; Weierstall U; Sawaya MR; Xu Q; Messerschmidt M; Williams GJ; Boutet S; Yefanov OM; White TA; Wang C; Ishchenko A; Tirupula KC; Desnoyer R; Coe J; Conrad CE; Fromme P; Stevens RC; Katritch V; Karnik SS; Cherezov V
    Cell; 2015 May; 161(4):833-44. PubMed ID: 25913193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system.
    Kurtz TW; Pravenec M
    Am J Hypertens; 2008 Aug; 21(8):852-9. PubMed ID: 18535538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Which strategy is more effective for the treatment of cardiovascular disease: high-dose angiotensin II type 1 receptor antagonist monotherapy or combination therapy?
    Miura S; Saku K
    Am J Cardiovasc Drugs; 2008; 8(2):88-90. PubMed ID: 18422392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.
    Kiya Y; Miura S; Fujino M; Imaizumi S; Karnik SS; Saku K
    Clin Exp Hypertens; 2010 Jan; 32(2):129-36. PubMed ID: 20374187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis.
    Silveira KD; Coelho FM; Vieira AT; Barroso LC; Queiroz-Junior CM; Costa VV; Sousa LF; Oliveira ML; Bader M; Silva TA; Santos RA; Silva AC; Teixeira MM
    Peptides; 2013 Aug; 46():53-63. PubMed ID: 23727291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of peptide and nonpeptide antagonists of angiotensin II receptors on noradrenaline release in hypothalamus of rats with angiotensin II-induced increase of water intake.
    Stancheva S; Alova L; Stefanova M
    Pharmacol Rep; 2009; 61(6):1206-10. PubMed ID: 20081258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
    Michel MC; Foster C; Brunner HR; Liu L
    Pharmacol Rev; 2013 Apr; 65(2):809-48. PubMed ID: 23487168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
    Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
    J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo.
    Pavel J; Benicky J; Murakami Y; Sanchez-Lemus E; Saavedra JM
    Ann N Y Acad Sci; 2008 Dec; 1148():360-6. PubMed ID: 19120129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin receptor blockers: Focus on cardiac and renal injury.
    Arumugam S; Sreedhar R; Thandavarayan RA; Karuppagounder V; Krishnamurthy P; Suzuki K; Nakamura M; Watanabe K
    Trends Cardiovasc Med; 2016 Apr; 26(3):221-8. PubMed ID: 26169314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent progress in the treatment of cardiovascular disease using olmesartan.
    Miura S; Saku K
    Clin Exp Hypertens; 2014; 36(7):441-6. PubMed ID: 24164503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy.
    Zhang Z; Li Z; Cao K; Fang D; Wang F; Bi G; Yang J; He Y; Wu J; Wei Y; Song X
    J Hypertens; 2017 Jul; 35(7):1442-1456. PubMed ID: 28244896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II.
    Yasuda N; Akazawa H; Qin Y; Zou Y; Komuro I
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):393-9. PubMed ID: 18046542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.
    Smith DH
    Drugs; 2008; 68(9):1207-25. PubMed ID: 18547132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.